Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company that focuses on developing innovative medicines for central nervous system disorders. The company is known for its research and development efforts, led by key figures like Craig C. Hopkinson, who recently sold 9,000 shares at $30.38 each. Despite this sale, Hopkinson still holds 69,740 shares, reflecting his continued investment in the company.

Alkermes is making strategic moves to expand its portfolio, as seen in its recent acquisition deal with Avadel Pharmaceuticals plc. Valued at approximately $2.1 billion, this acquisition will bring Avadel's FDA-approved drug, Lumryz, into Alkermes' offerings. This move marks Alkermes' entry into the sleep medicine market, enhancing its capabilities in treating central disorders of hypersomnolence.

The acquisition involves an immediate payment of $18.50 per share, with an additional $1.50 contingent on FDA approval of Lumryz for idiopathic hypersomnia by 2028. This strategic acquisition is expected to close in the first quarter of 2026, as highlighted by the approval from both companies' boards of directors.

Alkermes' financial metrics provide insight into its market valuation. With a P/E ratio of 14.70, the market values its earnings positively. The company's price-to-sales ratio of 3.27 and enterprise value to sales ratio of 2.92 reflect a strong market valuation of its revenue and sales. Additionally, the enterprise value to operating cash flow ratio of 8.20 indicates a favorable market view of its cash flow.

Alkermes maintains a low debt-to-equity ratio of 0.041, showcasing its conservative approach to debt. The company's strong current ratio of 3.67 further highlights its ability to cover short-term liabilities with its assets. With an earnings yield of 6.80%, Alkermes offers a solid return on investment for its shareholders.